
|Articles|October 8, 2014
Collaboration Will Help Match the Right Patient With the Right Trial
The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.
Advertisement
med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
Press release:
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Primary Care Capacity Gaps Threaten Respiratory Prevention
5




